A TRIAL-BASED EUROQOL EQ-5D HEALTH UTILITY ANALYSIS IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC
Author(s)
Huang M, Pellissier J, Liao J
Merck & Co., Inc., North Wales, PA, USA
Presentation Documents
OBJECTIVES: This study evaluated health-related quality of life utility in advanced NSCLC patients who have experienced disease progression after platinum-containing cheomotherapy METHODS: This study examined EQ-5D data collected from patients enrolled in the KEYNOTE-010 trial, a multi-center, worldwide, randomized Phase II/III trial of pembrolizumab and docetaxel in patients with previously treated advanced NSCLC with PD-L1 positive tumors. Two approaches of defining health states are considered in analysing utility: time-to-death reflecting decline in cancer patient’s quality of life as they approach death, and progression-based health states. Generic health statuses assessed from the EQ-5D questionnaire were converted to population-based utility values using published algorithms. The utility scores from the pooled treatment groups are reported. RESULTS: Data came from 560 patients who had at least one evaluable EQ-5D record. Mean utility score for patients in progression-free and progressive disease state is 0.76 (95% CI 0.75, 0.77) and 0.69 (95% CI 0.66, 0.71), respectively. Mean utility showed a decrease on disease progression of 0.07, which is considered as clinically meaningful. Patients were split into five groups based on their time to death after the EQ-5D questionnaire was taken - over 360 days, 180–360 days, 90–180 days, 30–90 days, and under 30 days, and mean utility in each time-to-death category is 0.81(95% CI 0.79, 0.83),0.73 (95% CI 0.71, 0.75),0.69(95% CI 0.66, 0.72),0.60 (95% CI 0.56, 0.64) and 0.40 (95% CI 0.31, 0.48).the results showed a large decrease in utility in the 30 days prior to death. CONCLUSIONS: The results showed that quality of life for pre-treated advanced NSCLC patients rapidly deteriorates during the end of life period. Considerable deterioration of utility in NSCLC patients is associated with disease progression and time to death. The utility values estimated from the study will inform economic evaluations of treatments in pre-treated advanced NSCLC.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCN198
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities
Disease
Oncology